STING1 and cancer: In cancer, an expanding body of evidence implicates disruption of the STING1-mediated IFN response with immune escape, resulting instead in noncanonical activation of the NFκB pathway downstream of STING1, and in downregulation of homologous recombination through PARP1 (16–18).